MK-0482

BIOLOGICAL5 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Carcinoma, Non-Small-Cell LungNeoplasmsRelapsed or Refractory Acute Myeloid LeukemiaRelapsed or Refractory Chronic Myelomonocytic Leukemia

Phase 1

A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)

CompletedNCT03918278

Merck Sharp & Dohme LLCNeoplasms

Start: 2019-06-19End: 2025-06-09Updated: 2025-06-25

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

RecruitingNCT04165070

Merck Sharp & Dohme LLCCarcinoma, Non-Small-Cell Lung

Start: 2019-12-19End: 2032-02-13Target: 450Updated: 2026-03-16

A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)

TerminatedNCT05038800

Merck Sharp & Dohme LLCRelapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia

Start: 2021-09-26End: 2023-12-11Updated: 2025-05-21

Phase 2

KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

CompletedNCT04165083

Merck Sharp & Dohme LLCCarcinoma, Non-Small-Cell Lung

Start: 2019-12-19End: 2025-10-31Updated: 2025-11-26

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

CompletedNCT04165096

Merck Sharp & Dohme LLCCarcinoma, Non-Small-Cell Lung

Start: 2020-01-21End: 2025-05-28Updated: 2025-06-25

Related Papers

Phase 1 study of the anti–immunoglobulin-like transcript 3 (ILT3) monoclonal antibody (mAb) MK-0482 + pembrolizumab (pembro) + paclitaxel for previously untreated advanced triple negative breast cancer (TNBC).

Journal of Clinical Oncology2025-05-28

KEYMAKER-U01 substudy 01A: Phase 1/2 study of pembrolizumab plus ifinatamab deruxtecan (I-DXd) or patritumab deruxtecan (HER3-DXd) with or without chemotherapy in untreated stage IV non–small-cell lung cancer.

Journal of Clinical Oncology2025-05-28

Phase 1 study of anti–immunoglobulin-like transcript 3 (ILT3) monoclonal antibody MK-0482 + pembrolizumab + gemcitabine + nab-paclitaxel (Gem/Nab-P) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).

Journal of Clinical Oncology2024-06-01

Phase 1 study of anti–immunoglobulin-like transcript 3 (ILT3) monoclonal antibody (mAb) MK-0482 + pembrolizumab (pembro) in patients with recurrent inoperable glioblastoma (GBM).

Journal of Clinical Oncology2024-06-01

Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial

Journal for ImmunoTherapy of Cancer2023-06-0123 citations

Phase 1b Trial of Anti-Immunoglobulin-like Transcript 3 Monoclonal Antibody MK-0482 Monotherapy in Relapsed/Refractory Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia

Blood2022-11-151 citations

Phase 1 first-in-human study of anti–ILT3 mAb MK-0482 as monotherapy and in combination with pembrolizumab in advanced solid tumors: Dose escalation results.

Journal of Clinical Oncology2022-06-016 citations